新型布鲁顿酪氨酸激酶抑制剂奥布替尼研究进展

doi:10.20047/j.issn1673-7210.2023.07.07

Abstract
Figure/Table
References (43)
Related Citation (15)

Download: PDF (690 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Orelabrutinib, a novel Bruton’s tyrosine kinase (BTK) inhibitor, is a class Ⅰ innovative drug independently developed in China. Its emergence brings new therapeutic methods for the treatment of lymphoma patients, especially the patients with relapsed/refractory mantle cell lymphoma and relapsed/refractory chronic lymphocytic leukemia/small cell leukemia. BTK is a key kinase in the B-cell antigen receptor signaling pathway and is crucial to the proliferation and survival of malignant B cells, thus it is a promising target for the treatment of B-cell malignant lymphoma. Therefore, this paper reviews the mechanism of action of BTK inhibitor and the basic information of listed BTK inhibitors, summarizes the pharmacological properties and clinical data of Orelabrutinib, and sorts out the latest clinical research progress of Orelabrutinib so far, and proposed that Orelabrutinib is the most potential BTK inhibitor at present and candidate drug for BTK inhibitor combination therapy.

Key words： Orelabrutinib Bruton’s tyrosine kinase inhibitor Clinical research Security

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yuhao MAO Fei LI Xiaokang

Cite this article:

LI Yuhao MAO Fei LI Xiaokang. Research progress of new Bruton’s tyrosine kinase inhibitor Orelabrutinib[J]. 中国医药导报, 2023, 20(7): 37-41.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.07.07 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I7/37

[1] Yu H，Wang X，Li J，et al. Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma [J]. Mol Ther Oncolytics，2021，21：158-170.
[2] Lorenzo-Vizcaya A，Fasano S，Isenberg DA. Bruton’s Tyrosine Kinase Inhibitors：A New Therapeutic Target for the Treatment of SLE? [J]. Immunotargets Ther，2020，9：105-110.
[3] 卜凡丹，刘新月.BTK抑制剂治疗套细胞淋巴瘤的研究进展[J].临床血液学杂志，2016，29（3）：255-258.
[4] Honigberg LA，Smith AM，Sirisawad M，et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy [J]. Proc Natl Acad Sci U S A，2010，107（29）：13075-13080.
[5] Mohamed AJ，Yu L，B?覿ckesj?觟 CM，et al. Bruton’s tyrosine kinase（Btk）：function，regulation，and transformation with special emphasis on the PH domain [J]. Immunol Rev，2009， 228（1）：58-73.
[6] 王姝，黄文海，沈正荣.布鲁顿酪氨酸激酶靶向药物的研究进展[J].中国现代应用药学，2020，37（24）：3063-3072.
[7] Qiu Y，Kung HJ. Signaling network of the Btk family kinases [J]. Oncogene，2000，19（49）：5651-5661.
[8] 北京诺诚健华医药科技有限公司.芳香族酰胺类衍生物、其制备方法及其在医药上的应用：中国，201310485048. 1 [P].2013-10-16.
[9] 北京诺诚健华医药科技有限公司.制备6-（1-丙烯酰基哌啶-4-基）-2-（4-苯氧基苯基）尼克酰胺的工艺：中国，CN 113454066 A [P].2021-09-28.
[10] 杜鹏，王璐璐，郑稳生，等.固体分散体载体材料研究新进展[J].中国医药生物技术，2021，16（4）：339-342.
[11] 北京诺诚健华医药科技有限公司.6-（1-丙烯酰基哌啶-4-基）-2-（4-苯氧基苯基）尼克酰胺的晶型：中国，CN 112654607 A [P].2021-04-23.
[12] 北京诺诚健华医药科技有限公司.6-（1-丙烯酰基哌啶-4-基）-2-（4-苯氧基苯基）尼克酰胺的固体分散体：中国，CN 113038936 A [P].2021-06-25.
[13] 娄安琦，余俊先，程子昭，等.布鲁顿氏酪氨酸激酶（BTK）抑制剂与难治性套细胞淋巴瘤[J].中国临床药理学与治疗学，2021，26（6）：680-686.
[14] Dhillon S. Orelabrutinib：First Approval [J]. Drugs，2021， 81（4）：503-507.
[15] Xu W，Song Y，Wang T，et al. Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma：Updated Long Term Results of Phase Ⅱ Study [J]. Blood，2021，138（1）：2638-2638.
[16] Song Y，Song Y，Liu L，et al. Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma：A Multicenter，Open-Label，Phase Ⅱ Study [J]. Blood，2020，136（1）：1.
[17] Song Y，Song Y，Liu L，et al. Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma：A Multicenter，Open- Label，Phase Ⅱ Study [J]. Blood，2019，134（1）：755.
[18] The U.S. Food and drug administration. FULL PRESCRIBING INFORMATION OF IBRUTINIB [EB/OL]. （2013- 11-13）[2022-02-11]. https：//www.accessdata.fda.gov/dru gsatfda_docs/label/2013/205552s000lbl.pdf.
[19] The U.S. Food and drug administration. FULL PRESCRIBING INFORMATION OF ACALABRUTINIB [EB/OL]. （2017-10-31）[2022-02-11]. https：//www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf.
[20] The U.S. Food and drug administration. FULL PRESCRIBING INFORMATION OF ZANUBRUTINIB [EB/OL]. （2019-11-14）. [2022-02-11]. https：//www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf.
[21] 小野薬品工業株式会社.ベレキシブル錠（VELEXBRU Tablets）[EB/OL]. （2020-05-18）. [2022-02-11]. https：//zy.yaozh.com/data/pdf/00068689.pdf.
[22] 无锡合全药业有限公司.奥布替尼片说明书 [EB/OL]. （2020- 12-25）[2022-02-11]. https：//zy.yaozh.com/instruct/sms20 210831/19.pdf.
[23] Wang ML，Blum KA，Martin P，et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib：updated safety and efficacy results [J]. Blood，2015，126（6）：739-745.
[24] Wang M，Rule S，Zinzani PL，et al. Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma：Long-Term Efficacy and Safety Results from a Phase 2 Study [J]. Blood，2020，136（1）：38-39.
[25] Wang M，Rule S，Zinzani PL，et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma（ACE-LY- 004）：a single-arm，multicentre，phase 2 trial [J]. Lancet，2018，391（10121）：659-667.
[26] Song Y，Zhou K，Zou D，et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma：long-term efficacy and safety results from a phase 2 study [J]. Blood，2022，139（21）：3148-3158.
[27] Song Y，Zhou K，Zou D，et al. Abstract EP789：ZANUBRU TINIB（ZANU）IN PATIENTS（PTS）WITH RELAPSED/ REFRACTORY（R/R）MANTLE CELL LYMPHOMA（MCL）：LONG-TERM EFFICACY AND SAFETY RESULTS FROM A PHASE 2 STUDY [C]// 26th Congress of the European Hematology Association ABSTRACT BOOK，Online：EHA2021 Virtual Congress，2021：362.
[28] Xu W，Song Y，Wang T，et al. Updated Results from the Phase Ⅱ Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia [J]. Blood，2020，136（1）：26-27.
[29] Xu W，Song Y，Li Z，et al. Safety，Tolerability and Efficacy of Orelabrutinib，Once a Day，to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia [J]. Blood，2019，134（1）：4319.
[30] O’Brien S，Furman RR，Coutre S，et al. Single-agent ibrutinib in treatment-na?觙ve and relapsed/refractory chronic lymphocytic leukemia：a 5-year experience [J]. Blood，2018，131（17）：1910-1919.
[31] Byrd JC，Wierda WG，Schuh A，et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia：updated phase 2 results [J]. Blood，2020，135（15）：1204-1213.
[32] Xu W，Yang S，Zhou K，et al. Zanubrutinib for patients with relapsed or refractory chronic lymphocytic leukemia [J]. Hematol Oncol，2019，37：87-88.
[33] Xu W，Yang S，Zhou K，et al. Abstract EP639： ZANUBRU TINIB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA： 34-MONTH FOLLOW-UP RESULTS [C]// 26th Congress of the European Hematology Association ABSTRACT BOOK，Online：EHA2021 Virtual Congress，2021：286-287.
[34] Zhou D，Jin J，Fu Z，et al. Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patients [J]. Blood，2021，138（1）：46.
[35] Treon SP，Tripsas CK，Meid K，et al. Ibrutinib in previously treated Waldenstr?觟m’s macroglobulinemia [J]. N Engl J Med，2015，372：1430-1440.
[36] Owen RG，McCarthy H，Rule S，et al. Acalabrutinib monotherapy in patients with Waldenstr?觟m macroglobulinemia：a single-arm，multicentre，phase 2 study [J]. Lancet Haematol，2020，7（2）：e112-e121.
[37] Trotman J，Opat S，Gottlieb D，et al. Zanubrutinib for the treatment of patients with Waldenstr?觟m macroglobulinemia：3 years of follow-up [J]. Blood，2020，136（18）：2027-2037.
[38] Yu T，Wang L，Ni X，et al. Orelabrutinib，a Selective Bruton’s Tyrosine Kinase（BTK）Inhibitor in the Treatment of Primary Immune Thrombocytopenia（ITP）[J]. Blood，2021，138（1）：3172.
[39] Li R，Zhu X，Liu S，et al. Orelabrutinib，an irreversible inhibitor of Bruton’s tyrosine kinase（BTK），for the treatment of Systemic Lupus Erythematosus（SLE）：results of a randomized，double-blind，placebo-controlled，phase Ⅰb/Ⅱa dose-finding study [J]. Ann Rheum Dis，2022，81（1）：210.
[40] Shan L，Shi H，Ji B，et al. Medicinal Chemistry Strategies for the Development of Bruton’s Tyrosine Kinase Inhibitors against Resistance [J]. J Med Chem，2022，65（11）：7415- 7437.
[41] Herman SEM，Montraveta A，Niemann CU，et al. The Bruton Tyrosine Kinase（BTK）Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia [J]. Clin Cancer Res，2017，23（11）：2831-2841.
[42] Song Y，Xu W，Song Y，et al. Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies [J]. Blood，2020，136（1）：43.
[43] Kaptein A，Bruin G，Hoek ME，et al. Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies [J]. Blood，2018，132（1）：1871.